The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•2 July 2026•

1 min read

Moderna Stock Surges 7% on FDA Flu Shot Support and Oncology Pipeline Progress

Key Facts

1Moderna stock surged over 7% after its flu shot received unanimous backing from an FDA advisory panel.

2The company revealed significant pipeline progress in oncology and autoimmune diseases, including an in vivo CAR-T program.

In a move reflecting the company's successful pivot toward diversifying its medical portfolio beyond COVID-19 vaccines, Moderna shares recorded a strong rally of over 7%. This momentum followed a unanimous recommendation from an FDA advisory panel supporting the company's flu vaccine candidate. Additionally, the company revealed significant pipeline progress in oncology and autoimmune diseases, including its innovative in vivo CAR-T program.

This positive development comes as major biotech firms like Pfizer and BioNTech seek to offset declining pandemic-related sales, with market data showing relative stability in sector peers following these announcements. Per market data, Moderna's focus on mRNA technology for cancer treatment places it in direct competition with drug development programs at Merck, which previously reported promising results in joint trials with Moderna for melanoma treatment.

Technically, MRNA shares settled at $72.50 (at close July 01, 2026), after reaching an intraday high of $73.91. Investors are now monitoring upcoming U.S. economic data, including the Michigan Consumer Sentiment index scheduled for release on June 26, for signals on broader market sentiment that could impact risk appetite in the growth and biotech sectors.